País: Canadá
Língua: inglês
Origem: Health Canada
SALMETEROL (SALMETEROL XINAFOATE); FLUTICASONE PROPIONATE
GLAXOSMITHKLINE INC
R03AK06
SALMETEROL AND FLUTICASONE
25MCG; 250MCG
AEROSOL, METERED DOSE
SALMETEROL (SALMETEROL XINAFOATE) 25MCG; FLUTICASONE PROPIONATE 250MCG
INHALATION
120 DOSES
Prescription
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0238341006; AHFS:
APPROVED
2001-12-21
_ _ _ _ _Page 1 of 70_ PR ADVAIR DISKUS fluticasone propionate and salmeterol inhalation powder USP Pr ADVAIR DISKUS _100_ 100 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate salt) Pr ADVAIR DISKUS _250_ 250 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate salt) Pr ADVAIR DISKUS _500_ 500 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate salt) PR ADVAIR fluticasone propionate and salmeterol pressurised inhalation, suspension BP Pr ADVAIR _125_ 125 mcg fluticasone propionate and 25 mcg salmeterol (as the xinafoate salt) Pr ADVAIR _250_ 250 mcg fluticasone propionate and 25 mcg salmeterol (as the xinafoate salt) Corticosteroid and Bronchodilator for Oral Inhalation GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 Date of Revision: June 17, 2020 Submission Control No: 237271 _© 2020 GSK group of companies or its licensor_ Trademarks are owned by or licensed to the GSK group of companies. _ _ _ _ _Page 2 of 70_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................ 3 SUMMARY PRODUCT INFORMATION ............................................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ......................................................................................................................... 4 WARNINGS AND PRECAUTIONS ........................................................................................................ 4 ADVERSE REACTIONS ........................................................................................................................ 15 DRUG INTERACTIONS ........................................................................................................................ 24 DOSAGE AND ADMINISTRATION.......................................................................... Leia o documento completo